Spyre Therapeutics Inc
Research Spyre Therapeutics Inc (SYRE) on Bullrun: market cap USD 9.45B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSYRE
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 9.45B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 36.20M
- Free cash flow-USD 69.88M
Valuation Snapshot
latest market cap is USD 9.45B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 155.20M | -USD 169.25M | n/a | -2.09 | USD 85.72M | n/a | USD 715.24M |
| FY2024 | USD 0 | -USD 208.02M | -USD 157.41M | n/a | -3.73 | USD 89.42M | n/a | USD 517.80M |
| FY2023 | USD 886.00K | -USD 338.79M | -USD 99.91M | n/a | 13.76 | USD 188.89M | USD 0 | USD 184.02M |
| FY2022 | USD 2.33M | -USD 83.82M | -USD 80.18M | n/a | -24.86 | USD 34.86M | USD 4.63M | USD 50.31M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 9.45B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.56B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.40B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 775.17M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 27.68M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 234.44M | n/a | n/a | n/a |
About Spyre Therapeutics Inc
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Spyre Therapeutics Inc's market cap?
Spyre Therapeutics Inc's market capitalization is USD 9.45B.
What does Spyre Therapeutics Inc do?
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).